|
122
|
| 487 |
GSK3B
|
|
affects_quantity of
|
Amyloid beta peptide
|
|
| 864 |
Lithium
|
|
affects_activity of
|
Amyloid beta peptide
|
|
| 14051 |
Amyloid beta peptide
|
|
increases_activity of
|
GSK3B
|
|
|
11527574
|
Alzheimer disease
|
|
247
|
| 1019 |
Amyloid beta peptide
|
|
affects_activity of
|
Alzheimer disease
|
|
|
16944319
|
Alzheimer disease
|
|
273
|
| 1111 |
Alzheimer disease
|
|
increases_quantity of
|
Amyloid beta peptide
|
in brain extracellular space
|
| 1112 |
circadian sleep/wake cycle, wakefulness
|
|
affects_quantity of
|
Amyloid beta peptide
|
in brain interstitial fluid
|
| 1119 |
HCRT
|
|
increases_quantity of
|
Amyloid beta peptide
|
in brain interstitial fluid
|
|
19779148
|
Alzheimer disease
|
|
322
|
| 1273 |
NCSTN-del
|
|
decreases_quantity of
|
Amyloid beta peptide
|
decreased gamma-secretase cleavage by deletion mutations of NCSTN;
|
| 14059 |
NCSTN
|
|
affects_quantity of
|
Amyloid beta peptide
|
|
|
10993067
|
Alzheimer disease
|
|
381
|
| 14072 |
PSEN1
|
|
affects_quantity of
|
Amyloid beta peptide
|
|
| 21383 |
amyloid-beta formation
|
|
affects_quantity of
|
Amyloid beta peptide
|
|
|
12048259
|
Alzheimer disease
|
|
418
|
| 1876 |
Alzheimer disease
|
|
increases_quantity of
|
Amyloid beta peptide
|
|
| 1954 |
Amyloid beta peptide
|
|
decreases_activity of
|
AKT1
|
|
| 1955 |
Amyloid beta peptide
|
|
interacts (colocalizes) with
|
AKT1
|
|
| 14040 |
Amyloid beta peptide
|
|
interacts (colocalizes) with
|
PDPK1
|
|
| 14041 |
inclusion body myositis
|
|
increases_quantity of
|
Amyloid beta peptide
|
|
|
19144826
|
Alzheimer disease
|
|
427
|
| 1867 |
Amyloid beta peptide
|
|
decreases_phosphorylation of
|
AKT1
|
if AKT is insulin-induced;
|
| 1868 |
Amyloid beta peptide
|
|
decreases_activity of
|
AKT1
|
if AKT is insulin-induced;
|
| 1879 |
Amyloid beta peptide
|
NOT |
decreases_activity of
|
phosphatidylinositol 3-kinase signaling
|
|
| 1993 |
Amyloid beta peptide
|
|
decreases_activity of
|
myotube differentiation
|
|
| 1994 |
Amyloid beta peptide
|
|
decreases_activity of
|
nucleus organization
|
by increasing the pyknotic nuclei
|
|
19144826
|
Alzheimer disease
|
|
457
|
| 2082 |
Amyloid beta peptide
|
|
affects_activity of
|
insulin receptor signaling pathway
|
|
| 2083 |
Amyloid beta peptide
|
|
increases_quantity of
|
MAPT-hyperphos
|
|
| 2084 |
Amyloid beta peptide
|
|
increases_activity of
|
neuronal cytoskeletal lesion
|
|
| 2091 |
Amyloid beta peptide
|
|
affects_quantity of
|
Insulin
|
in CNS; if levels of APP / Amyloid beta peptide in AD are increased then level of insulin is reduced
|
| 12996 |
Insulin
|
|
increases_transport of
|
Amyloid beta peptide
|
from the trans-Golgi-network to the plasma membrane
|
| 14606 |
Amyloid beta peptide
|
|
increases_quantity of
|
MAPT-hyperphos
|
|
|
19712582
|
Alzheimer disease
|
|
505
|
| 2509 |
PSEN1
|
|
increases_quantity of
|
Amyloid beta peptide
|
|
| 2510 |
PSEN2
|
|
increases_quantity of
|
Amyloid beta peptide
|
|
| 14082 |
Amyloid beta peptide
|
|
increases_quantity of
|
amyloid beta deposits
|
|
| 14083 |
APP
|
|
increases_quantity of
|
Amyloid beta peptide
|
|
|
11943765
|
Alzheimer disease
|
|
580
|
| 3095 |
Lithium
|
|
decreases_expression of
|
Amyloid beta peptide
|
|
| 3096 |
Lithium
|
|
decreases_quantity of
|
Amyloid beta peptide
|
in brain; of mice
|
| 3104 |
Gamma-secretase complex
|
|
increases_quantity of
|
Amyloid beta peptide
|
|
| 3136 |
CTNNB1
|
NOT |
affects_quantity of
|
Amyloid beta peptide
|
if CTNNB1 (beta-catenin) is overexpressed
|
|
12761548
|
Alzheimer disease
|
|
605
|
| 3171 |
Bisdemethoxycurcumin
|
|
decreases_quantity of
|
Amyloid beta peptide
|
|
|
19090986
|
Alzheimer disease
|
|
613
|
| 3297 |
Insulin
|
|
affects_quantity of
|
Amyloid beta peptide
|
in the cell; depending on insulin concentration
|
|
19237574
|
Diabetes mellitus, type II
Insulin resistance
|
|
642
|
| 3418 |
Uncharged thioflavin-T derivative
|
|
interacts (colocalizes) with
|
Amyloid beta peptide
|
|
|
11554609
|
Alzheimer disease
|
|
645
|
| 3449 |
Lithium
|
|
decreases_quantity of
|
Amyloid beta peptide
|
|
|
14651959
|
Alzheimer disease
|
|
651
|
| 3452 |
Roscovitine
|
|
increases_quantity of
|
Amyloid beta peptide
|
in brain
|
| 3453 |
CDK5
|
|
affects_quantity of
|
Amyloid beta peptide
|
in brain
|
|
14651959
|
Alzheimer disease
|
|
652
|
| 3483 |
PSEN1-mut
|
NOT |
affects_activity of
|
Amyloid beta peptide
|
|
|
18189321
|
Alzheimer disease
|
|
658
|
| 3550 |
Amyloid beta peptide
|
|
decreases_activity of
|
Mitochondrial respiratory chain complex IV
|
|
|
19337449
|
Alzheimer disease
|
|
663
|
| 3552 |
Alzheimer disease
|
|
increases_quantity of
|
Amyloid beta peptide
|
in mitochondria of brain
|
|
17708691
|
Alzheimer disease
|
|
667
|
| 3585 |
Amyloid beta peptide
|
|
interacts (colocalizes) with
|
PPIF
|
in mitochondrion
|
|
19268425
|
Alzheimer disease
|
|
681
|
| 3667 |
PSEN1-p.L286V
|
|
increases_quantity of
|
Amyloid beta peptide
|
|
|
9051814
|
Alzheimer disease
|
|
706
|
| 3878 |
Amyloid beta peptide
|
|
is localized in
|
brain
|
in mitochondria
|
| 3897 |
Amyloid beta peptide
|
|
is localized in
|
mitochondrion
|
in brain
|
|
15659604
|
Alzheimer disease
|
|
719
|
| 4032 |
LiCl
|
|
increases_quantity of
|
Amyloid beta peptide
|
|
|
16014628
|
Alzheimer disease
|
|
742
|
| 4184 |
APH1A
|
|
affects_quantity of
|
Amyloid beta peptide
|
|
|
15634781
|
Alzheimer disease
|
|
792
|
| 4543 |
APOE-mut
|
|
affects_quantity of
|
Amyloid beta peptide
|
|
| 4548 |
Amyloid beta peptide
|
|
affects_activity of
|
amyloidosis
|
|
| 4551 |
Amyloid beta peptide
|
|
affects_quantity of
|
amyloid beta deposits
|
|
|
19449461
|
Alzheimer disease
|
|
843
|
| 4998 |
Amyloid beta peptide
|
|
increases_expression of
|
SERTAD1
|
in neurons
|
|
20237268
|
Alzheimer disease
|
|
864
|
| 5123 |
A4 (novobiocin analogue)
|
|
decreases_activity of
|
Amyloid beta peptide
|
in neurons
|
|
17276679
|
Alzheimer disease
|
|
908
|
| 5415 |
Amyloid beta peptide
|
|
affects_activity of
|
NMDA receptor complex
|
|
| 5419 |
Amyloid beta peptide
|
|
increases_quantity of
|
Reactive oxygen species
|
in neuron; through an NMDA receptor-dependent process
|
| 5420 |
Amyloid beta peptide
|
|
decreases_activity of
|
mitochondrial depolarization
|
in astrocytes; partly due to activation of phospholipase
|
| 5528 |
Resveratrol
|
|
decreases_quantity of
|
Amyloid beta peptide
|
via a mechanism that involves the proteasome
|
| 5543 |
Curcumin
|
|
interacts (colocalizes) with
|
Amyloid beta peptide
|
and inhibits Abeta aggregation
|
|
19191039
|
Alzheimer disease
|
|
924
|
| 5595 |
Epigallocatechin 3-gallate
|
|
decreases_quantity of
|
Amyloid beta peptide
|
in primary neurons; derived from Swedish mutant APP-overexpressing mice TgAPPswl line 2576
|
|
16177050
|
Alzheimer disease
|
|
933
|
| 5643 |
Epigallocatechin 3-gallate
|
|
affects_quantity of
|
Amyloid beta peptide
|
in murine neuron-like cells (N2a)
|
|
16177050
|
Alzheimer disease
|
|
952
|
| 5827 |
Insulin
|
|
affects_quantity of
|
Amyloid beta peptide
|
|
| 5828 |
LEP
|
|
affects_quantity of
|
Amyloid beta peptide
|
|
|
20385830
|
Alzheimer disease
|
CIDeRplus